Introducing seasonal influenza vaccine in low-income countries: an adverse events following immunization survey in the Lao People’s Democratic Republic

Manilay Phengxay, a Sara A. Mirza, b Rita Reyburn, a Anonh Xeuatvongsa, c Christian Winter, a Hannah Lewis, a Sonja J. Olsen, b Reiko Tsuyuoka, a Viengphone Khandhamaly, d Francisco S. Palomeque, b Joseph S. Bresee, b Ann C. Moen, b Andrew L. Corwin, d for the Lao PDR Field Epidemiology Training Cohort Team*

aLao PDR Country Office Western Pacific Regional Office WHO, Vientiane, Lao People’s Democratic Republic. bInfluenza Division, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA. cNational Immunization Program, Lao PDR Ministry of Health, Vientiane, Lao People’s Democratic Republic. dLao PDR Country Office, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.

Correspondence: Manilay Phengxay, Lao PDR Country Office, Western Pacific Region, WHO, P.O. Box 343 Vientiane, Lao People’s Democratic Republic. E-mail: PhengxayM@wpro.who.int

*Lao PDR Field Epidemiology Training Cohort Team members are in Appendix 1.

Accepted 13 November 2014. Published Online 03 January 2015.

Objective In 2012, Lao PDR introduced seasonal influenza vaccine in pregnant women, persons aged ≥50 years, persons with chronic diseases, and healthcare personnel. We assessed adverse events following immunization (AEFI).

Methods We used a multistage randomized cluster sample design to interview vaccine recipients.

Findings Between April and May 2012, 355 902 were vaccinated. Of 2089 persons interviewed, 261 (12.5%) reported one or more AEFI. The most commonly reported AEFIs were local reactions. No hospitalizations or deaths were reported; 16% sought medical care. Acceptance and awareness of vaccination were high.

Conclusions Following the introduction of seasonal influenza vaccine in Lao PDR, self-reported adverse events were mild.

Keywords Adverse events following immunization, influenza vaccine, Lao PDR.

Introduction Influenza vaccines have been used for >60 years and have proven safe and effective.1,2 However, use of seasonal influenza vaccine in South-East Asia is sparse, with the majority of doses available for cost in the private sector.3 In 2012, the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) recommended annual influenza vaccination for five high-risk groups: pregnant women, the elderly, persons with a chronic illness, young children, and healthcare personnel.4 The successful deployment of pandemic vaccine in 2009 led the Lao People’s Democratic Republic (Lao PDR) Ministry of Health to enter into a public–private partnership with Walgreens Company, facilitated by WHO and U.S. Centers for Disease Control and Prevention (CDC), to distribute 375 000 donated doses of 2011–2012 Northern Hemisphere formulation of the trivalent inactivated seasonal influenza vaccine Fluvirin® (Novartis).5,6 Lao PDR’s National Immunization Program (NIP) has a passive surveillance system to identify adverse events following immunization (AEFI). The Ministry of Health in collaboration with WHO and CDC conducted a survey to actively assess AEFI following introduction of the vaccine.

Methods The seasonal influenza vaccine campaign was conducted in Lao PDR from April 23, 2012 to May 8, 2012. Four key populations were targeted: pregnant women, persons aged ≥50 years, persons with chronic disease, and all healthcare personnel.6 Children were not included as a target group because (i) Fluvirin® was indicated for use in persons ≥4 years, and (ii) children aged 4–8 required two doses 4 weeks apart, a logistical challenge deemed not feasible this year. Four provinces were selected for the campaign: Vientiane Capital, Savannakhet, Champasak, and Luang Prabang. Vaccination was voluntary and free to eligible
persons. No additional incentive was provided. An information, education, and communication campaign was conducted prior to vaccination.

We estimated statistical power to detect common serious adverse events (e.g., any hospitalization) that might occur as often as 0.5–1.0% and assumed this would not differ by target population. Using this frequency, a sample of 2000 vaccinated recipients would allow sufficient precision (relative standard error below 30%) to identify common serious AEFIs. We targeted approximately 2500 vaccine recipients for the survey, estimating 20% non-response. A multistage stratified cluster sampling method was used to obtain a representative sample from the four target populations vaccinated. In stage 1, four districts per province were randomly selected for inclusion. In stage 2, three vaccinated villages with total population >500 persons were randomly selected per district for of 12 villages per province. All pregnant women who received vaccine and at least 15 persons >50 years of age and 15 persons with chronic disease were selected using a random number table from the village vaccine register. Healthcare personnel from three central hospitals were selected in Vientiane Capital province, all provincial hospitals (n = 3), and all district hospitals (n = 16), and villages in the selected provinces were sampled.

We used a standardized AEFI questionnaire to collect information on demographics, campaign awareness, and AEFIs for participants who responded yes to the screening question: “Did you experience any symptoms after seasonal flu vaccination?” An AEFI was defined as having one of the symptoms could be reported; frequencies were not mutually exclusive; date of onset and duration were also recorded.

Adverse events were categorized as mild (grade 1), moderate (grade 2), severe (grade 3), or life threatening (grade 4) using a modified Solicited Adverse Events scale.9 For reporting of rare events, such as anaphylactic shock, stroke, or death, we relied on reporting from the passive NIP AEFI surveillance system. Pregnancy outcome, if available, was assessed. Among those reporting an AEFI, health-seeking behavior and limitation of daily activities were assessed. Lao PDR Field Epidemiology Training (Lao FET) trainees conducted the survey over a three-week period following vaccine administration. Verbal consent was obtained prior to interview.

Descriptive analysis was conducted using EpiData (Odense, Denmark). Variance and 95% confidence intervals around AEFI point estimates were obtained by the Taylor series linearization method.7 The survey was approved by the Lao PDR Ministry of Health and exempted from IRB review as a public health evaluation program.

**Results**

A total of 355 902 persons received seasonal influenza vaccine during the campaign; 29 213 (8.2%) were pregnant women, 22 767 (6.4%) healthcare personnel, 96 626 (27%) were persons with chronic illness, and 207 296 (58%) were persons ≥50 years of age. A total of 2089 persons from the target populations were interviewed for the survey (Table 1). Respondents were equally distributed across the four provinces; the median age was 47 years (range, 5–94 years) and more women than men participated. The majority (94%) of survey participants (excluding healthcare personnel) received vaccine in their village, followed by district and provincial hospitals. Median time between vaccination and survey interview was 7 days (range, 2–22 days). All interviews were completed within 3 weeks of vaccine administration.

Two hundred and sixty-one (12.5%) survey participants self-reported a mild or moderate local reaction or systemic

| Table 1. Demographics of survey respondents by target group, Lao PDR 2012 |
|---------------------------------------------------------------|
| Pregnant women (n = 187, 9%) | Persons ≥50 years of age (n = 819, 39%) | Persons with chronic disease (n = 733, 35%) | Healthcare personnel (n = 343, 16%) | Total (n = 2082)* |
| Sex | | | | |
| Females | 187 (100%) | 528 (64%) | 544 (74%) | 274 (80%) | 1533 (74%) |
| Males | 291 (35%) | 189 (26%) | 69 (20%) | 549 (26%) |
| Age in years | | | | |
| Median (range) | 25 (15–45) | 58 (50–94) | 42 (5–86) | 40 (19–65) | 47 (5–94) |
| Luang Prabang | 62 (33%) | 227 (28%) | 170 (23%) | 61 (18%) | 520 (25%) |
| Vientiane | 16 (8.6%) | 172 (21%) | 187 (26%) | 160 (47%) | 535 (26%) |
| Savanakhet | 33 (18%) | 227 (28%) | 166 (23%) | 63 (18%) | 489 (23%) |
| Champasak | 76 (41%) | 193 (24%) | 210 (29%) | 59 (17%) | 538 (26%) |

*Of the 2089 total interviewed respondents, seven people reported being in an “other” risk group and are not displayed in the table.
The frequency by type was as follows: generalized weakness 28 (1.3%), nausea 38 (1.8%), headache 40 (1.9%), fever 40 (1.9%), and local reaction 56 (2.7%). No severe or life-threatening AEFI (grades 3 or 4) or hospitalizations were reported in this assessment. Among participants reporting an AEFI, the majority were persons with chronic diseases or persons ≥50 years of age (Table 2). Among persons with an AEFI, the most common symptoms were local reactions and the frequency of local reactions among the vaccine and placebo groups typically had similar rates.\(^{12}\) Of the AEFI, the most common symptoms were local reactions and the frequency of local reactions among the vaccine and placebo groups typically had similar rates.\(^{12}\)

Discussion

Following introduction of a seasonal influenza vaccine campaign in Lao PDR, the numbers of self-reported AEFI were low and mild in nature, as expected from this well-evaluated vaccine.\(^{1,2}\) Further, influenza vaccine was considered highly acceptable and nearly three-fourths of respondents had heard of influenza vaccine and the campaign prior to vaccination, indicating successful sensitization and social mobilization campaigns prior to the campaign.

The frequency of AEFI identified in the Lao population was similar to that seen in other studies of inactivated influenza vaccine.\(^{8,11}\) In placebo-controlled trials among adults, vaccine and placebo groups typically had similar rates of headache, myalgia, and malaise. A randomized controlled trial (RCT) of persons age 60 or older found a similar frequency of local reactions among the vaccine and placebo group (18%) and no difference in systemic adverse events.\(^{12}\) Further, influenza vaccine was considered highly acceptable and nearly three-fourths of respondents had heard of influenza vaccine and the campaign prior to vaccination, indicating successful sensitization and social mobilization campaigns prior to the campaign.

Our observational results were similar to the results from a RCT of healthy working adults; the vaccine group frequency of fever was 6.2%, headache 10.8%, and malaise 16%.\(^{13}\)

This assessment was based on self-reported interview and was not confirmed by a clinician; therefore, objective classification of a mild, moderate, or severe event was difficult to ascertain. With a small sample size, we likely missed rare, severe AEFI. However, given the novelty of the vaccine campaign in this adult population, such events were likely to have been reported in the passive surveillance system. The majority of AEFIs were reported among persons

---

**Table 2.** Prevalence of adverse events within 7 days following seasonal influenza vaccine, \(n = 2089\) vaccine recipients. Lao PDR 2012

| Target group                  | No. interviewed | % of all interviewed | AEFI | % of all AEFI (95% CI) |
|------------------------------|-----------------|----------------------|------|------------------------|
| Total                        | 2089            | 261                  | 12.5%|                        |
| Pregnant women               | 187             | 9.0%                 | 23   | 12.3% (7.9–16.7)       |
| Persons aged ≥50 years       | 819             | 39%                  | 73   | 8.9% (6.9–10.9)        |
| Persons with chronic disease | 733             | 35%                  | 98   | 13.4% (10.2–16.6)      |
| Healthcare personnel         | 343             | 16%                  | 67   | 19.5% (12.1–26.9)      |
| Others                       | 7               | 0.3%                 | 0    | 0%                     |
| Province                     |                 |                      |      |                        |
| Luang Prabang                | 520             | 25%                  | 58   | 11.2% (9.7–12.5)       |
| Vientiane capital            | 535             | 26%                  | 94   | 17.6% (11.7–23.5)      |
| Savannakhet                  | 489             | 23%                  | 40   | 8.2% (4.4–12.0)        |
| Champasak                    | 545             | 26%                  | 69   | 12.7% (8.1–17.3)       |
| Sex                          |                 |                      |      |                        |
| Female                       | 1539            | 74%                  | 210  | 13.6% (11.1–16.2)      |
| Male                         | 550             | 26%                  | 51   | 9.3% (6.0–12.6)        |
| Ethnic group                 |                 |                      |      |                        |
| Lao Loun                     | 1646            | 79%                  | 227  | 13.8%                  |
| Lao Theung                   | 418             | 20%                  | 33   | 7.9%                   |
| Lao Soung                    | 16              | 0.8%                 | 1    | 6.3%                   |
| Other                        | 9               | 0.4%                 | 0    | 0%                     |
≥50 years of age or with chronic disease, and it is likely that some reported events were associated with an existing underlying medical condition and not the vaccine. The survey found daily activities were not affected among most participants which further substantiates that reported AEFIs were likely mild to moderate.

Survey responses indicated a high level of satisfaction among vaccine recipients, likely due to self-selection bias. Future assessments to better ascertain levels of interest and acceptance of vaccine should be made among the general population. Our results indicate the NIP campaign to generate awareness of the vaccine was effective in reaching a majority of the targeted population, findings from this study attest to the feasibility of introducing seasonal influenza vaccine in low- and middle-income countries.

The success of this vaccine campaign was in large measure a function of integration with existing NIP systems which are ideally suited to deliver vaccine to populations with limited access to preventive health services in a short period of time. The use of the NIP also contributed to building trust and acceptance of the vaccine among government stakeholders and the local population.

Following the successful introduction of seasonal influenza vaccine in 2012, Lao PDR has developed a plan to continue to provide seasonal influenza vaccine to priority populations, with a focus on pregnant women and continued to provide seasonal influenza vaccine to priority populations. Establishing feasibility, safety, and acceptability of the introduction of a new vaccine provides additional evidence for countries to commit to pursuing a disease reduction strategy through vaccination policy.

Author contributions

Manilay Phengxay contributed to the design, execution, and analysis of the study and writing of the manuscript and final content. Sara Mirza contributed to the design, execution, and analysis of the study and writing of the manuscript and final content. Rita Reyburn contributed to the design, execution, and analysis of the study and reviewed final content. Anonh Xeuatvongsa contributed to the coordination, design, and execution of the study and reviewed final content. Christian Winter contributed to the design, execution, and writing of the manuscript and reviewed final content. Hannah Lewis contributed to the design execution and writing of the manuscript and reviewed final content. Sonja J. Olsen contributed to the analysis of the study and writing and editing of the manuscript and reviewed final content. Reiko Tsuyuoka contributed to the organization, design and execution of the study and reviewed final content. Francisco S. Palomeque contributed to the analysis of data and reviewed final content. Joseph Bresee contributed to the organization, design, analysis, and writing of the manuscript and reviewed final content. Ann Moen contributed to the organization, design, analysis, and writing of the manuscript and reviewed final content. Andrew Corwin contributed to the organization, design, analysis, and writing of the manuscript and reviewed final content. The Lao PDR Field Epidemiology Training Cohort Team3 listed by name (Appendix 1), collected all data, entered all data, and analyzed data for this project as part of their training module. They all reviewed final content and contributed to the final product.

Acknowledgements

The authors gratefully acknowledge all survey respondents and staff of the Lao PDR Ministry of Health National Immunization Program (NIP), National Emerging Infectious Disease Coordination Office (NEIDCO), National Center for Laboratory and Epidemiology (NCLE), and the Lao PDR FET program for their ongoing collaboration and expertise.
They also appreciate the support of the Walgreens Foundation for the 2012 seasonal influenza vaccine donation and are very appreciative for guidance and advice provided by Keith Feldon of the WHO WPRO EPI program Prabda Praphasiri of the CDC Thailand MOPH Vashonia Smith, Paul Gar-giuillo, Carrie Reed, Marc-Alain Widdowson, and Tim Uyeki of the CDC Influenza Division.

Funding

This project was funded by the Centers for Disease Control and Prevention (cooperative agreement number 5U51IP 000583) and the government of Lao PDR.

Disclosure

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the United States Centers for Disease Control and Prevention.

References

1 Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines recommendations of the advisory committee on immunization practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1–55.

2 Cox NJ, Subbarao K. Influenza. Lancet 1999; 354:1227–1282.

3 Gupta V, Dawood FS, Muangchana C et al. Influenza vaccination guidelines and vaccine sales in Southeast Asia: 2008–2011. PLoS ONE 2012; 7:e52842.

4 WHO. Meeting of the strategic advisory group of experts on immunization. April 2012-conclusions and recommendations. Wkly Epidemiol Rec 2012; 87:201–216.

5 World Health Organization. Report of the WHO Pandemic Influenza A (H1N1) Vaccine Deployment Initiative. WHO Press, 2012.

6 Centers for Disease Control and Prevention. Lao People’s Democratic Republic Launches Seasonal Flu Vaccination Program. 2012. Available at http://www.cdc.gov/flu/spotlights/vaccination-program-launch-lao.htm (Accessed 28 July 2014).

7 Lohr SL. Sampling: Design and Analysis. Pacific Grove, CA: Duxbury Press, 1999.

8 Vellozi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 2009; 27:2114–2120.

9 U.S. Department of Health and Human Services; Food and Drug Administration; Centers for Biological Evaluation and Research. Solicited AEFI Grading Scale. 2007 report on Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.

10 Lauritsen JM, Bruus M. EpiData Entry (Version 3.1). A Comprehensive Tool for Validated Entry and Documentation of Data. Odense, Denmark, The EpiData Association, 2008.

11 Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines recommendations of the advisory committee on immunization practices (ACIP), 2013–2014. MMWR Recomm Rep 2013; 62:1–43.

12 Govaert TM, Dinant GJ, Aretz K, Masurel N, Sprenger MJW, Knoottnerus JA. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ 1993; 307:988–990.

13 Nichol KL, Margolis KL, Lind A et al. Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial. Arch Intern Med 1996; 156:1546–1550.

14 Centers for Disease Control and Prevention. Laos and Nicaragua Protect High-Risk Persons from Influenza, with Help from Donor Coalition and CDC. 2013. Available at http://www.cdc.gov/flu/international/highlight-high-risk.htm (Accessed 30 July 2014).

Appendix 1

Bounlay Phommasack, Phengta Vongphrachanh, Bouaphanh Khamphaphongphane, Vien savanh Kittiphiphong, Khansay Sengsaya, Phonetavy Khodsimeuang, Phonephay Louangpaseuth, Khonesavanh Phanthavong, Phouthone Souliphone, Houmpheng Thionkeo, Khamphet Louanglad, Anousone Fongmany, Phoukhong Vorachansy, Boungnasith Khongsamphanh, Nouda Prasith, and Sisavath Phanatda.